Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia

26 Apr 2020

Abstract excerpt

Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different categories of drugs for concomitant disorders. Demented patients may take >6–10 drugs/day with the consequent risk for drug–drug interactions and adverse drug reactions (ADRs >80%) which accelerate cognitive decline. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsy research and treatment
Share to Pharmacogenetics and Drug Metabolism
Share to Pharmacological Effects and Toxicity Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32357528
DOI: 10.3390/ijms21093059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in DementiaPMID 32357528Read ↗

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 VariantsSemantic proximity Read ↗

Pharmacogenomics and therapeutic strategies for dementiaSemantic proximity Read ↗

Pharmacogenomics and therapeutic prospects in dementiaSemantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.Semantic proximity Read ↗

Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetics of Anxiety and Depression in Alzheimer’s DiseaseSemantic proximity Read ↗

Influence of pharmacogenetic factors on Alzheimer's disease therapeutics.Semantic proximity Read ↗

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read ↗

Pharmacogenomics for the treatment of dementia.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Pharmacogenomics in neurology: current state and future steps.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.